Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Receivables: 2011-2024

Historic Change in Receivables for Gyre Therapeutics (GYRE) over the last 13 years, with Dec 2024 value amounting to $5.3 million.

  • Gyre Therapeutics' Change in Receivables rose 177.17% to $1.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$2.0 million, marking a year-over-year increase of 18.42%. This contributed to the annual value of $5.3 million for FY2024, which is 1944.56% up from last year.
  • Per Gyre Therapeutics' latest filing, its Change in Receivables stood at $5.3 million for FY2024, which was up 1,944.56% from -$285,000 recorded in FY2023.
  • Gyre Therapeutics' Change in Receivables' 5-year high stood at $5.3 million during FY2024, with a 5-year trough of -$11.7 million in FY2020.
  • In the last 3 years, Gyre Therapeutics' Change in Receivables had a median value of -$285,000 in 2023 and averaged $1.1 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Change in Receivables slumped by 177.91% in 2020, and later spiked by 1,944.56% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Change in Receivables (Yearly) stood at -$11.7 million in 2020, then surged by 87.21% to -$1.5 million in 2021, then dropped by 8.23% to -$1.6 million in 2022, then soared by 82.39% to -$285,000 in 2023, then surged by 1,944.56% to $5.3 million in 2024.